The lead product candidate melflufen is currently being reviewed by the U.S. Food and Drug Administration, FDA, as a potential treatment for multiple myeloma. The FDA has granted the New Drug Application for melflufen a priority review and set a target date for a decision to February 28, 2021. The company is planning for a commercial launch in the US in the beginning of 2021.
Melflufen is the first drug candidate coming out of the company´s proprietary Peptide Drug Conjugate platform, PDC. Oncopeptides has recently submitted an Investigational New Drug application for its second drug candidate from this technology platform, OPD5.
Oncopeptides has established a new facility for pre-clinical drug development in Solna, Sweden, which provides adequate resources to further expand the development of the PDC-platform and generate new drug candidates.
Footprint in leading biotech hubs
The global headquarters is in Stockholm, Sweden, and the U.S. headquarters in Waltham, Massachusetts, outside of Boston. In addition, the company has an office in Los Altos, California.
Oncopeptides AB (publ) has 250 employees and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.